UNSPSC 85523512: Supplement right hand vein with autologous tissue substitute, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to supplement right hand vein with autologous tissue substitute, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 05UG37Z

UNSPSC 85523512 Supplement right hand vein with autologous tissue substitute, percutaneous approach is a Commodity code that shows no meaningful recent state and local procurement activity aligned with its medical-procedure scope. The six recent opportunities posted to state and local procurement channels between July and September 2026 — independent medical evaluations, surgical benefit carve-out programs, occupational health surveillance, youth detention medical services, pharmacy benefit management, and temporary health professional staffing — do not constitute procurement for the specific autologous tissue vein-supplementation procedure this code nominally describes. State and local governments solicit this code's work through health system purchasing, employee health benefit administration, and occupational health program management, but the recent opportunity sample does not surface demand for this particular surgical intervention.

Issuers across the recent sample include county health systems (Santa Clara County Health System), county boards of commissioners (Collier County), city retirement offices (City of Phoenix), municipal health plans (City of Long Beach), state transportation agencies (Washington State Department of Transportation on behalf of Washington State Ferries), and county juvenile justice departments (Harris County Juvenile Probation Department). Activity spans Arizona, California, Florida, and Washington, with geographically dispersed procurement offices managing health benefit, occupational medicine, and specialty provider contracting. Without recent solicitations specifically naming autologous tissue vein supplementation or matching the code's clinical scope, the code presents low pursuit priority in the current state and local market.